Pacific Life Insurance Fit Review for People With Heart Disease

Research Snapshot

Why Pacific Life Qualified for This Study

Questions This Section Answers

• Is Pacific Life a good choice for life insurance for people with heart disease?
• Why did only three of seven AI platforms name Pacific Life for heart disease life insurance?

Pacific Life qualified because its own published underwriting guide names cardiac conditions directly rather than treating all heart disease as one category. The impairment guide covers heart disease involving angina, angioplasty, bypass/CABG, heart attack, arrhythmia, valve conditions, and hypertension, and states these cases receive individual consideration or depend on severity and associated conditions ^[4].

It cleared the study's minimum-mention threshold of two platforms. Three of seven platforms named it during ranking discovery: deepseek at rank 2, kimi at rank 8, and perplexity at rank 10. That produces a 42.9% share of included platform responses and an average listed rank of 6.67. The remaining four platforms evaluated fit but did not name Pacific Life in their ranking output, so the mention count is lower than the fit-evaluation count.

The company also offers both term and permanent products relevant to this buyer, including Pacific Elite Term and Pacific Discovery Xelerator IUL, which lets a qualifying applicant choose between temporary and lifelong coverage ^[7]. For a broader view of how this carrier compares with others in the category, see the Life Insurance for People With Heart Disease consensus index.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for People With Heart Disease

Questions This Section Answers

• Which Pacific Life plan should a buyer with heart disease choose if they want convertible term coverage?
• Is Pacific Elite Term or Pacific Discovery Xelerator IUL the better Pacific Life option for a cardiac applicant?

The best initial candidate for most cardiac applicants is fully underwritten Pacific Elite Term. It offers 10-, 20-, and 30-year level-premium periods, full underwriting for all listed risk classes, and conversion to eligible Pacific Life cash-value insurance without additional underwriting for up to ten years after issue or attained age 70, subject to product terms ^[9].

Pacific Elite Term's published material lists issue ages of 18–75 for 10-year term, 18–65 for 20-year term, and 18–50 for 30-year term, with face amounts beginning at $750,000 in one source and $250,000 in another ^[9]. That face-amount conflict is unresolved in the supplied evidence and should be confirmed directly.

Pacific Discovery Xelerator IUL is the permanent alternative. Pacific Life describes up to $3 million of coverage without a medical exam for some applicants ages 25–60 with no major health impairments, subject to health, age, gender, occupational risk, application answers, and possible attending-physician-statement review ^[13]. That no-exam pathway should not be assumed available to a person with significant heart disease. One platform reported that the Xelerator IUL product could not be verified in public sources at all, so its cardiac underwriting criteria remain unclear (anthropic).

PL Promise Term also appears in the platform responses as a relevant product with accelerated, modified, and traditional underwriting pathways ^[14].

What the AI Platforms Agreed About

Questions This Section Answers

• Do AI platforms agree that Pacific Life will consider applicants with stable heart disease?
• What cardiac conditions does Pacific Life's underwriting guide actually address?

The clearest area of agreement is that Pacific Life underwrites cardiac impairments case by case rather than issuing blanket declines. Five of seven platforms described condition-specific cardiac underwriting, and the company's own impairment guide supports that reading ^[17].

Platforms also agreed on the existence of hard waiting periods after major cardiac events. The published guide identifies potential declines for uninvestigated unstable angina, angioplasty performed less than one month earlier, CABG less than three months earlier, myocardial infarction within six months, and valve surgery within six months ^[17]. Independent broker-hosted copies of Pacific Life guidance repeat the same thresholds ^[23].

A third point of agreement is that an attending physician statement is required for all listed heart-disease, arrhythmia, and myocardial-infarction cases, with requirements also applying to most valve-related cases ^[17]. For known coronary artery disease, a treadmill stress test is not required, but a resting EKG and full cardiac records are ^[27].

Platforms further agreed that heart disease disqualifies applicants from Pacific Life's accelerated underwriting pathways, pushing them into full traditional underwriting ^[29].

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• How long after a heart attack does Pacific Life consider an application?
• Does Pacific Life publish cardiac-specific rates or table ratings for heart disease applicants?

The sharpest conflict is the post-heart-attack waiting period. One platform reported a 6-month postponement ^[33], while another reported a 12-month postponement with Table 4+ ratings at 12 months and standard potential at 5+ years with normal ejection fraction ^[35]. The company's own guide supports the 6-month figure; the 12-month figure comes from independent industry analysis. Buyers should treat the longer period as the conservative planning assumption.

Platforms disagreed on overall fit rating. OpenAI, Anthropic, Google, and Kimi rated Pacific Life a "good" fit; DeepSeek, Grok, and Perplexity rated it "mixed." DeepSeek's review was conducted without search enabled, so its conclusion that no public cardiac underwriting guide exists conflicts with the guides other platforms retrieved (deepseek).

Pricing transparency is a shared uncertainty rather than a disagreement. No platform found a cardiac-specific premium, rate class table, or approval grid. One platform noted that table rating nomenclature varies between industry sources and is not disclosed by Pacific Life directly (anthropic). Another flagged that public sources conflict on exact recency thresholds and fine-grained class outcomes (perplexity).

Two product-level uncertainties remain open. One platform could not verify the Pacific Discovery Xelerator IUL in public documentation (anthropic). Another noted that whether Pacific Life offers any simplified-issue or guaranteed-issue product for cardiac applicants through subsidiaries was not captured in search results (kimi).

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What cardiac documentation will Pacific Life require from a heart disease applicant?
• Does Pacific Elite Term let a cardiac applicant convert to permanent coverage without new underwriting?

The most relevant capability is condition-specific underwriting. Pacific Life's guide lists heart disease involving angina, angioplasty, bypass/CABG, heart attack, arrhythmia, valve conditions, and hypertension, and applies individual consideration rather than blanket exclusion ^[38].

Documentation requirements are substantial. An attending physician statement is required for all listed heart-disease, arrhythmia, and myocardial-infarction cases ^[38]. For known coronary artery disease, requirements include a resting EKG and full cardiac records rather than a treadmill stress test ^[42]. One platform reported that a modified underwriting pathway requires an APS with evidence of physical exam and lab work within the past 12 months ^[44].

Conversion is a meaningful feature for this buyer. Pacific Elite Term offers conversion to eligible Pacific Life cash-value policies without additional underwriting for up to ten years after issue or attained age 70, with a minimum of two years, and a conversion credit available from year two equal to one annual term premium ^[45]. This protects future insurability if a cardiac condition worsens.

Pacific Elite Term also includes a Critical Illness Rider covering heart attack as a qualifying event, plus a Terminal Illness Rider and Chronic Illness Rider ^[45]. One platform reported the Critical Illness Rider is available for all issue ages and risk classes including substandard ratings.

Independent analysis placed Pacific Life's cardiac underwriting as competitive among major carriers, citing 12-month postponement post-MI with potential Table 4+ ratings at 12 months and standard potential at 5+ years with normal ejection fraction, plus Table 2–4 ratings for controlled atrial fibrillation depending on rate control and anticoagulation ^[48]. That analysis is independent and directional, not an official rate book.

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does Pacific Life cost per month for a heart disease applicant, and what fees apply?
• What happens to Pacific Elite Term premiums after the level-premium period ends?

No individualized premium can be verified without age, coverage amount, term, tobacco status, diagnosis, dates of cardiac events, test results, treatment, medications, and other underwriting information (openai). Pacific Life does not publish premiums or rate classes for life insurance applicants, and no cardiac-specific pricing information is available publicly ^[51].

The one firm cost figure across platforms is a $60 annual policy fee on Pacific Elite Term, reported in the product brochure and repeated by multiple platforms ^[53]. Level premiums apply only during the selected level-premium period; continuation afterward causes annual premium increases ^[53].

For Pacific Discovery Xelerator IUL, premium loads and monthly policy charges reduce or affect cash value, and exact amounts require an illustration and policy contract ^[57]. Indexed accounts carry caps on upside crediting and a guaranteed minimum interest-crediting rate.

Substandard risk may add flat extra charges or table ratings applied as a percentage of base premium, with specific rates not disclosed (anthropic). One platform reported that substandard table ratings (Table A through Table H) add flat extras or percentage multipliers up to roughly 300% of standard rates, with the cap dropping to Table D for ages 76–80 ^[59]. Industry data cited by another platform indicates table ratings increasing premiums 25% per table ^[60].

Contract terms are only partly documented. Pacific Life states it is licensed to issue insurance in all states except New York (openai). The reviewed sources do not establish a specific free-look period, surrender-charge schedule, lapse grace-period outcome, or cancellation-refund rule for a given state (openai, deepseek). Buyers comparing carriers across the wider life insurance market should request state-specific contract provisions in writing.

Best Suited For

Questions This Section Answers

• Who is Pacific Life best suited for among buyers with a heart disease history?
• Is Pacific Life a good fit for a buyer with controlled atrial fibrillation?

Pacific Life is best suited to applicants whose cardiac condition is stable, treated, investigated, and sufficiently remote from any recent heart attack, angioplasty, bypass, or valve surgery (openai). Platforms converged on a similar profile: stable coronary artery disease managed with medication, angioplasty or bypass surgery completed at least three months prior with normal cardiac function, controlled atrial fibrillation or other managed arrhythmias, and mild valve issues without other cardiac comorbidities ^[61].

It also suits applicants who want traditionally underwritten term coverage, particularly Pacific Elite Term, and who value possible conversion to an eligible Pacific Life permanent policy without new underwriting during the stated conversion period ^[62].

Buyers with complete cardiac documentation and consistent cardiology follow-up are favored. Independent analysis flagged Pacific Life as favorable for applicants with strong cardiology records and no comorbidities, and noted controlled atrial fibrillation on anticoagulation can qualify for Table 2–4 ratings ^[63].

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose Pacific Life for life insurance after a heart disease diagnosis?
• Will Pacific Life decline an applicant with an implantable cardioverter-defibrillator or low ejection fraction?

Applicants with an uninvestigated or unstable condition, a heart attack within the prior six months, angioplasty within the prior month, CABG within the prior three months, or valve surgery within the prior six months are poor candidates because the published guide identifies potential declines for these situations ^[64].

Applicants seeking guaranteed issue, simplified issue, or a cardiac-specific acceptance guarantee should look elsewhere. Pacific Life requires full medical underwriting for cardiac histories, and heart disease disqualifies applicants from accelerated underwriting programs ^[67].

Applicants whose main objective is the fastest no-exam approval are also poorly matched. Pacific Discovery Xelerator IUL's no-exam pathway is described for applicants with no major health impairments and is therefore not clearly suitable for significant heart disease ^[71].

One platform reported that applicants with active congestive heart failure and ejection fraction below 35–40%, or with an implantable cardioverter-defibrillator, are likely to be declined (anthropic). Independent analysis cited by another platform placed the ejection fraction concern threshold at below 40–45%, with 55%+ considered normal ^[72]. Those thresholds are industry analysis, not Pacific Life's published criteria.

When Another Option May Be Better

Questions This Section Answers

• What is a better alternative to Pacific Life for a buyer who had a heart attack within the last six months?
• When should a heart disease buyer use a multi-carrier broker instead of applying directly to Pacific Life?

A multi-carrier independent broker can obtain informal or pre-underwriting opinions from insurers whose cardiac underwriting is more favorable for the specific diagnosis, and that step is worth taking before submitting a formal application to Pacific Life (openai).

Guaranteed-issue or final-expense insurance may be more appropriate when traditional underwriting produces a decline, although coverage limits may be lower and premiums may be higher relative to the benefit (openai). One platform cited guaranteed-issue whole life from Mutual of Omaha, Gerber Life, and AIG with ages 50–85, caps at $25,000, and a two-year graded death benefit ^[74]. Another reported guaranteed-issue pricing of $120–$156 per month for $20,000 at age 65 ^[75].

A simpler term policy from another carrier may be preferable when the buyer needs only temporary income protection and does not need cash-value accumulation or conversion (openai). Another permanent policy may be preferable when the buyer needs permanent coverage but cannot accept IUL charges, indexed-crediting caps, or lapse sensitivity (openai).

For recent events specifically, platforms suggested carriers with shorter postoperative waiting periods or specialized cardiac impairment programs, and named Protective Life, Banner Life, and North American Company as comparison points for post-MI table ratings (anthropic, kimi). One platform noted Banner Life may consider applicants at six months post-MI (kimi). Those carrier names are platform-reported and were not independently verified in this review.

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with Pacific Life before signing a contract?
• Can a heart disease applicant get an informal underwriting decision before formally applying?

Ask whether Pacific Life will provide an informal underwriting assessment before a formal application, based on the exact diagnosis, event dates, procedures, symptoms, medications, test results, ejection fraction if relevant, and cardiologist records (openai).

Ask which specific APS, ECG, stress-test, echocardiogram, catheterization, laboratory, and hospital records are required, and who pays for any testing (openai, anthropic).

Ask whether the applicant would be rated, postponed, or declined, and what table rating or flat extra would apply (openai, anthropic).

Ask whether the applicant qualifies for Pacific Elite Term at the desired age, face amount, term length, and state, and confirm the actual minimum face amount, since supplied sources conflict between $250,000 and $750,000 ^[76].

Ask whether Pacific Discovery Xelerator IUL's no-exam pathway is unavailable because of the applicant's cardiac history, and whether full underwriting would still be required ^[78].

Ask for the guaranteed premium schedule, including the premium after the level term period, and the total annual policy cost ^[76].

For the IUL, ask for guaranteed values, current illustrated values, caps, participation rates, monthly charges, surrender charges, loan provisions, and lapse consequences ^[78].

Ask which riders are available in the applicant's state and what additional charges or exclusions apply, and confirm the conversion deadlines and eligible target policies for Pacific Elite Term ^[80].

Ask how a parental death from heart disease before age 50 affects eligibility for Preferred tiers, since one platform reported Pacific Life disqualifies applicants from top tiers under that rule ^[81].

Ask for current financial-strength ratings from A.M. Best, S&P, Moody's, and Fitch, because the reviewed Pacific Life investor-relations source did not provide a specific current rating in accessible page content ^[82].

Final AI Consensus Verdict

Pacific Life is a good, not strong, fit for a U.S. consumer with a history of heart disease. Its published underwriting material is unusually relevant because it specifically addresses major cardiac conditions and allows individual consideration ^[83]. The best initial candidate is generally fully underwritten Pacific Elite Term for a stable and well-documented history ^[86].

Pacific Discovery Xelerator IUL may be relevant when permanent coverage and cash-value features are needed, but its no-exam pathway is not clearly intended for applicants with major cardiac impairments, and its cost and complexity require a personalized illustration ^[87]. One platform could not verify the product in public documentation at all (anthropic).

The consensus is not unanimous. Four platforms rated the fit "good" and three rated it "mixed," and the post-heart-attack waiting period is reported as either six or twelve months depending on the source. A multi-carrier broker should compare Pacific Life's informal underwriting decision with other carriers before the buyer submits a formal application (openai).

How This Review Was Produced

This review synthesizes fit-research responses from seven AI platforms that evaluated Pacific Life for the specific use case of life insurance for people with heart disease. The research date is 2026-09-22. Three of the seven platforms named Pacific Life during ranking discovery; all seven produced fit evaluations.

Platform responses were treated as platform-reported evidence, not independently verified facts. Company-owned citations materially outnumber independent citations in the supplied evidence, so company claims are not described here as independently verified. Where platforms disagreed, both positions are reported rather than resolved.

Methodology Limitations

Platform-reported research dates differ from the authoritative run date. Anthropic reported 2026-01-20 and DeepSeek reported 2026-06-11, while the remaining platforms and the study itself are dated 2026-09-22. Those platform dates are provenance metadata and do not independently prove freshness.

DeepSeek's response was produced with search disabled, so its conclusion that no public cardiac underwriting guide exists conflicts with guides other platforms retrieved and should be weighted accordingly.

The supplied URLs were collected from platform responses and were not independently validated by the writer stage. Citations are platform-reported evidence, not independently verified facts.

No public source reviewed provides a cardiac-specific approval table, guaranteed rate class, or premium quote. The main cardiac impairment guide is marked for financial-professional use only, so applicants may need an agent or broker to interpret it. Product availability, state variations, rider availability, and financial-strength ratings should be verified directly because product documents and ratings can change.